Inspired by the success of blocking PD-1/PD-L1 interaction for immunotherapy [14,23,24,25,26,27], inhibition of BTLA/HVEM binding showed potential for the treatments of infectious diseases and cancers. This evidence concerns the gene PDCD1 and cancer.